Panbela Therapeutics Performance
| PBLADelisted Stock | USD 2.06 0.11 5.07% |
The company holds a Beta of 1.73, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Panbela Therapeutics will likely underperform. Panbela Therapeutics right now holds a risk of 0.0%. Please check Panbela Therapeutics value at risk, rate of daily change, relative strength index, as well as the relationship between the kurtosis and market facilitation index , to decide if Panbela Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Panbela Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong essential indicators, Panbela Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 11.9 M | |
| Total Cashflows From Investing Activities | -656 K |
Panbela |
Panbela Therapeutics Relative Risk vs. Return Landscape
If you would invest 206.00 in Panbela Therapeutics on September 1, 2024 and sell it today you would earn a total of 0.00 from holding Panbela Therapeutics or generate 0.0% return on investment over 90 days. Panbela Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Panbela, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Panbela Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Panbela Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Panbela Therapeutics, and traders can use it to determine the average amount a Panbela Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PBLA |
Based on monthly moving average Panbela Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Panbela Therapeutics by adding Panbela Therapeutics to a well-diversified portfolio.
Panbela Therapeutics Fundamentals Growth
Panbela Stock prices reflect investors' perceptions of the future prospects and financial health of Panbela Therapeutics, and Panbela Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Panbela Stock performance.
| Return On Equity | -7.98 | ||||
| Return On Asset | -1.92 | ||||
| Current Valuation | 8.64 M | ||||
| Shares Outstanding | 3.48 M | ||||
| Price To Book | 3.22 X | ||||
| EBITDA | (34.76 M) | ||||
| Cash And Equivalents | 2.53 M | ||||
| Cash Per Share | 0.12 X | ||||
| Total Debt | 6.84 M | ||||
| Book Value Per Share | (16.57) X | ||||
| Cash Flow From Operations | (15.28 M) | ||||
| Earnings Per Share | (157.02) X | ||||
| Total Asset | 4.98 M | ||||
| Retained Earnings | (91.09 M) | ||||
About Panbela Therapeutics Performance
By analyzing Panbela Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Panbela Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Panbela Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Panbela Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Panbela Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Things to note about Panbela Therapeutics performance evaluation
Checking the ongoing alerts about Panbela Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Panbela Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Panbela Therapeutics is not yet fully synchronised with the market data | |
| Panbela Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Panbela Therapeutics currently holds 6.84 M in liabilities. Panbela Therapeutics has a current ratio of 0.55, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Panbela Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (34.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Panbela Therapeutics currently holds about 2.53 M in cash with (15.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. |
- Analyzing Panbela Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Panbela Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Panbela Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Panbela Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Panbela Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Panbela Therapeutics' stock. These opinions can provide insight into Panbela Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Panbela Stock
If you are still planning to invest in Panbela Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Panbela Therapeutics' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |